Company: CERO
Filing Date: 2025-08-22
Form Type: 10-Q
Source: 0001213900-25-079898
Chunk: 173

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-22
Form: 10-Q
Item: Item 8
Chunk 173
---
 the shares of Series D Preferred Stock then outstanding, unless
the holder waives such right to receive such payment. The equity value of the Common Stock underlying the Series D Preferred Stock
is calculated using the greatest closing sale price of the Common Stock on any trading day immediately preceding such bankruptcy
Series D Triggering Event and the date the Company makes the entire payment required.

Change
of Control Exchange. Upon a change of control of the Company, each holder may require the Company to exchange the holder’s
shares of Series D Preferred Stock for consideration equal to the Change of Control Election Price (as defined in the Series D
Certificate of Designations), to be satisfied at the Company’s election in either (x) cash or (y) rights convertible
into such securities or other assets to which such holder would have been entitled with respect to such shares of Common Stock had such
shares of Common Stock been held by such holder upon consummation of such corporate event.

Company
Optional Redemption. At any time the Company shall have the right to redeem in cash all, but not less than all, the shares of Series D
Preferred Stock then outstanding at a 25% redemption premium to the greater of (x) the amount of shares being redeemed, and (y) the
equity value of the Common Stock underlying the Series D Preferred Stock. The equity value of the Common Stock underlying the Series D
Preferred Stock is calculated using the greatest closing sale price of the Common Stock on any trading day immediately preceding
the date the Company notifies the holders of the Company’s election to redeem and the date the Company makes the entire payment
required.

Fundamental
Transactions. The Certificate of Designations prohibit the Company from entering specified fundamental transactions (including, without
limitation, mergers, business combinations and similar transactions) unless the Company (or the Company’s successor) assumes in
writing all of the Company’s obligations under the Certificate of Designations and the other Transaction Documents (as defined
in the Series D Certificate of Designations).

Voting
Rights. The holders of the Series D Preferred Stock shall have no voting power and no right to vote on any matter at any time,
either as a separate series or class or together with any other series or class of share of capital stock, and shall not be entitled
to call a meeting of such holders for any purpose nor shall they be entitled to participate in any meeting of the holders of Common Stock,
except